PLVAP
Plasmalemma vesicle-associated protein
Also known as: FELS, gp68, PLVAP_HUMAN, PV-1, PV1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9BX97
- Gene
- PLVAP
- Ensembl
- ENSG00000130300
- Chromosome
- 19
- Canonical length
- 442 aa
- Protein class
- Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Plasma membrane,Centrosome,Cytosol
- Quaternary structure
- Homodimer
OverviewNCBI Gene
Predicted to enable identical protein binding activity. Involved in MAPK cascade; positive regulation of cellular extravasation; and tumor necrosis factor-mediated signaling pathway. Located in caveola and cell surface. Implicated in congenital diarrhea. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
442 residues, UniProt reviewed canonical sequence.
>Q9BX97|PLVAP
1 MGLAMEHGGS YARAGGSSRG CWYYLRYFFL FVSLIQFLII LGLVLFMVYG NVHVSTESNL
61 QATERRAEGL YSQLLGLTAS QSNLTKELNF TTRAKDAIMQ MWLNARRDLD RINASFRQCQ
121 GDRVIYTNNQ RYMAAIILSE KQCRDQFKDM NKSCDALLFM LNQKVKTLEV EIAKEKTICT
181 KDKESVLLNK RVAEEQLVEC VKTRELQHQE RQLAKEQLQK VQALCLPLDK DKFEMDLRNL
241 WRDSIIPRSL DNLGYNLYHP LGSELASIRR ACDHMPSLMS SKVEELARSL RADIERVARE
301 NSDLQRQKLE AQQGLRASQE AKQKVEKEAQ AREAKLQAEC SRQTQLALEE KAVLRKERDN
361 LAKELEEKKR EAEQLRMELA IRNSALDTCI KTKSQPMMPV SRPMGPVPNP QPIDPASLEE
421 FKRKILESQR PPAGIPVAPS SGLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PLVAP can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.49
- Highest tissue expression
- 419 nTPM
Expression across tissuesHPA
Tissue
- thyroid gland: 419 nTPM
- adipose tissue: 269 nTPM
- breast: 205 nTPM
- kidney: 176 nTPM
- spleen: 161 nTPM
- blood vessel: 146 nTPM
Single-cell type
- vascular endothelial cells: 584 nCPM
- lymphatic endothelial cells: 39 nCPM
- pdcs: 37 nCPM
- microglia: 33 nCPM
- thymic myoid cells: 19 nCPM
- salivary myoepithelial cells: 17 nCPM
Immune cell
- plasmacytoid DC: 35 nTPM
- intermediate monocyte: 6.2 nTPM
- non-classical monocyte: 2.7 nTPM
- total PBMC: 0.6 nTPM
- myeloid DC: 0.4 nTPM
- classical monocyte: 0.2 nTPM
Brain region
- choroid plexus: 35 nTPM
- cerebral cortex: 4.9 nTPM
- white matter: 4.6 nTPM
- medulla oblongata: 3.7 nTPM
- spinal cord: 3.6 nTPM
- pons: 3.5 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PLVAP.
Disease | AllUniProt
Conditions PLVAP is implicated in, by any mechanism.
- Diarrhea 10, protein-losing enteropathy type (DIAR10) MIM:618183
Disease | GeneticClinVar
8 pathogenic / likely-pathogenic of 273 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Diarrhea 10, protein-losing enteropathy type
- See cases
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.97
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.55
- DepMap mean gene effect
- -0.1
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- developmental process
- MAPK cascade
- positive regulation of cellular extravasation
- regulation of vascular permeability
- tumor necrosis factor-mediated signaling pathway
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Plasmalemma vesicle-associated protein
- PV-1 protein (PLVAP)
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PLVAP as an antibody target. Whether an autoantibody or antibody against PLVAP could matter depends on whether native PLVAP is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PLVAP is annotated at the cell surface, where native PLVAP is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label PLVAP as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...